ArticleMolecular biology reports2026
A versatile plasmid platform for auxotrophic complementation in attenuated Mycobacterium bovis BCG.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycobacterium bovis BCG is widely used as a vaccine vector due to its safety, genetic stability, and immunomodulatory properties. However, current expression systems for BCG transformation rely on antibiotic resistance genes, raising biosafety concerns. Therefore, alternative strategies—such as the use of auxotrophic strains—are highly desirable. Our group previously employed BioBrick™ technology to construct the pUP500 plasmid series containing various mycobacterial promoters. We engineered these plasmids for the auxotrophic complementation of BCG ΔLeuD, a leucine-auxotrophic strain, using an antibiotic-free and BioBrick™-compatible approach. METHODS AND
resultsThe auxotrophic complementation cassette pAN-leuD was cloned into pUP500 plasmids. Subsequently, the egfp gene was inserted downstream of the promoters, the kanamycin resistance gene was removed, and fluorescence was assessed by flow cytometry, qPCR and confocal microscopy in BCG grown in 7H9 medium and inside macrophages. Auxotrophic complementation was confirmed by growth of transformants in non-selective medium and analysis of leuD expression, and plasmid stability was evaluated along six BCG generations. Strains harboring plasmids containing the pAN and HspX promoters exhibited stronger fluorescence levels both in vitro and within macrophages. In contrast, the 18 kDa promoter demonstrated marked activation specifically in the intracellular environment, driving robust gene expression inside macrophages. These expression patterns were significantly higher compared to strains carrying the Ag85B or Hsp60 promoters, as well as to the negative control. Except for the Hsp60 construct, all plasmids exhibited robust in vitro stability across six consecutive passages, supporting their potential as reliable expression systems for heterologous antigens in therapeutic and vaccine applications.
conclusionsWe developed five BioBrick™-compatible plasmids with distinct promoters for auxotrophic complementation and antigen expression in BCG ΔLeuD, eliminating the need for antibiotic-based selection. This standardized plasmid series reduces vector-related variability in comparative studies and provides a diverse promoter repertoire that may enhance the stability and efficacy of recombinant BCG ΔLeuD strains, representing a valuable advancement for prophylactic and therapeutic vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.